Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6 | P05231 | 8/20 | 0.63 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449984 | 0.92 | IL6 (0.66) | IL6 | |
| SCHEMBL3119444 | 0.91 | IL6 (0.68) | IL6BRD4GRIN1GRIN2B | |
| SCHEMBL447162 | 0.90 | IL6 (0.64) | IL6 | |
| SCHEMBL446106 | 0.90 | IL6 (0.69) | IL6GRIN1GRIN2B | |
| SCHEMBL1917117 | 0.89 | IL6 (0.70) | IL6 | |
| SCHEMBL448819 | 0.89 | IL6 (0.71) | IL6 | |
| SCHEMBL14878816 | 0.89 | IL6 (0.47) | IL6GRIN1GRIN2BSMN1; SMN2 | |
| SCHEMBL446286 | 0.87 | IL6 (0.73) | IL6 | |
| SCHEMBL451854 | 0.86 | IL6 (0.76) | IL6 | |
| SCHEMBL1919265 | 0.86 | IL6 (0.74) | IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664221-B2 | Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-03-04 | — | — | US | claimed |
| US-20140045842-A1 | METHOD FOR TREATING AN INFLAMMATORY DISEASE BY ADMINISTERING A 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUND CONTAINING A PHENYL GROUP HAVING A SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-02-13 | — | — | US | claimed |
| US-8569493-B2 | Method for treating a homeostasis-related disease or glaucoma by administering a 1,2,3,4-tetrahyroquinoxaline compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | claimed |
| EP-2151436-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED THEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-04-24 | — | — | EP | claimed |
| US-8193187-B2 | 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | claimed |
| US-20120129866-A1 | METHODS FOR PREVENTING OR TREATING METABOLIC DISEASES, INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, ALLERGIC DISEASES, CENTRAL NERVOUS SYSTEM DISEASES, CARDIOVASCULAR DISEASES, HOMEOSTASIS-RELATED DISEASES OR GLAUCOMA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | claimed |
| US-20110166151-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVES CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | claimed |
| EP-2327699-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT | Santen Pharmaceutical Co., Ltd (JP) | 2011-06-01 | — | — | EP | claimed |
| US-20100137307-A1 | NOVEL 1,2,3,4,-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED TEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | claimed |
| EP-2151436-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED THEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2010-02-10 | — | — | EP | claimed |
| US-8664221-B2 | Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8664221-B2 | Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8664221-B2 | Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20140045842-A1 | METHOD FOR TREATING AN INFLAMMATORY DISEASE BY ADMINISTERING A 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUND CONTAINING A PHENYL GROUP HAVING A SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20140045842-A1 | METHOD FOR TREATING AN INFLAMMATORY DISEASE BY ADMINISTERING A 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUND CONTAINING A PHENYL GROUP HAVING A SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20100137307-A1 | NOVEL 1,2,3,4,-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED TEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137307-A1 | NOVEL 1,2,3,4,-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED TEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| WO-2010029986-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT | 参天製薬株式会社 (JP) | 2010-03-18 | — | — | WO | disclosed |
| EP-2151436-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED THEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2010-02-10 | — | — | EP | disclosed |
| EP-2151436-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED THEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129866-A1 | METHODS FOR PREVENTING OR TREATING METABOLIC DISEASES, INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, ALLERGIC DISEASES, CENTRAL NERVOUS SYSTEM DISEASES, CARDIOVASCULAR DISEASES, HOMEOSTASIS-RELATED DISEASES OR GLAUCOMA | GPR39, ACOX1, ATXN2L | IL6 1153/4885BRD4 2557/4885GRIN1 525/4885 |
| US-20140045842-A1 | METHOD FOR TREATING AN INFLAMMATORY DISEASE BY ADMINISTERING A 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUND CONTAINING A PHENYL GROUP HAVING A SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS A SUBSTITUENT | UACA, PKLR, CYSLTR1 | IL6 23/4885BRD4 1603/4885GRIN1 1042/4885 |
| US-20110166151-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVES CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT | NR3C1, GRK4, MC2R | IL6 1109/4885BRD4 1599/4885GRIN1 61/4885 |
| US-20100137307-A1 | NOVEL 1,2,3,4,-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED TEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY | NR3C2, NR3C1, NR5A1 | IL6 1624/4885BRD4 2096/4885GRIN1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.